Liposome-Encapsulated Rutin Attenuates Cisplatin-Induced Ototoxicity via Suppression of P53-Associated Oxidative Injury
Source abstract
Abstract
Cisplatin (CDDP) is a widely used chemotherapeutic agent, but its clinical applications are constrained by ototoxic side effects. Currently, few effective strategies exist to prevent or mitigate CDDP-induced ototoxicity. Rutin is known for its cell-protective effects by reducing oxidative stress and inhibiting apoptosis. However, its limited water solubility and inefficient delivery to the inner ear pose substantial challenges. To address this, rutin is encapsulated in liposomes (Lip-Rutin) for nanoscale drug delivery, leveraging its antioxidant properties. Lip-Rutin markedly attenuates CDDP-induced oxidative stress damage and apoptosis, demonstrating a protective effect on OC-1 cells. The efficacy of Lip-Rutin in safeguarding against CDDP-induced ototoxicity is further validated through in vivo studies. Consequently, Lip-Rutin emerges as a promising novel therapeutic agent for combating CDDP-induced ototoxicity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hearing, Cochlea, Tinnitus, Genetics · Vestibular and auditory disorders · Ear Surgery and Otitis Media
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Otorhinolaryngology-Head and Neck Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Institute of Otorhinolaryngology-Head and Neck Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hubei Province Clinical Research Center for Deafness and Vertigo
School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Funding
Innovative Research Group Project of the National Natural Science Foundation of China
References (42)
Show source-provided references
1. 10.3390/ijms2406592010.3390/ijms24065920 ↗
2. 10.1039/D2MO00220E10.1039/D2MO00220E ↗
3. 10.1021/acs.chemrestox.9b0020410.1021/acs.chemrestox.9b00204 ↗
4. 10.1016/j.molmed.2019.08.00210.1016/j.molmed.2019.08.002 ↗
5. 10.1016/j.canep.2022.10220310.1016/j.canep.2022.102203 ↗
6. 10.1200/OP.22.0071010.1200/OP.22.00710 ↗
7. 10.1001/jamaoto.2020.004710.1001/jamaoto.2020.0047 ↗
8. 10.3389/fcell.2021.75018510.3389/fcell.2021.750185 ↗
9. 10.1002/pmrj.1204210.1002/pmrj.12042 ↗
10. 10.1016/j.ijpharm.2020.12018010.1016/j.ijpharm.2020.120180 ↗
11. 10.2217/nnm-2022-012110.2217/nnm-2022-0121 ↗
12. Chen F, Jiang Q, Xu B, Huang Y, Xu K, Xu X, Yu D, Chen Y, Wang X. Ototoxicity-alleviating and cytoprotective allomelanin nanomedicine for efficient sensorineural hearing loss treatment. ACS Nano. 2024; https://doi.org/10.1021/acsnano.4c10610.
13. 10.3389/fncel.2017.0033810.3389/fncel.2017.00338 ↗
14. 10.1016/j.ejpb.2021.03.00810.1016/j.ejpb.2021.03.008 ↗
15. 10.1007/s40272-022-00550-x10.1007/s40272-022-00550-x ↗
16. 10.1002/ptr.690410.1002/ptr.6904 ↗
17. 10.1155/2018/624101710.1155/2018/6241017 ↗
18. 10.2174/092986732466617100311415410.2174/0929867324666171003114154 ↗
19. 10.1002/ptr.639110.1002/ptr.6391 ↗
20. 10.1016/j.biopha.2017.10.00110.1016/j.biopha.2017.10.001 ↗
21. Ghanbari-Movahed M, Mondal A, Farzaei MH, Bishayee A. Quercetin- and rutin-based nano-formulations for cancer treatment: A systematic review of improved efficacy and molecular mechanisms. Phytomed Int J Phytother Phytopharm. 2022;97: Article 153909.
22. 10.1016/j.jpba.2020.11364210.1016/j.jpba.2020.113642 ↗
23. 10.3390/ph1509111510.3390/ph15091115 ↗
24. Meyer H, Stöver T, Fouchet F, Bastiat G, Saulnier P, Bäumer W, Lenarz T, Scheper V. Lipidic nanocapsule drug delivery: Neuronal protection for cochlear implant optimization. Int J Nanomedicine. 2012;7:2449–2464.
25. 10.1016/j.ijpharm.2021.12057110.1016/j.ijpharm.2021.120571 ↗
26. 10.1007/s13197-011-0251-110.1007/s13197-011-0251-1 ↗
27. 10.1016/j.foodchem.2014.03.00510.1016/j.foodchem.2014.03.005 ↗
28. 10.1016/j.redox.2019.10136410.1016/j.redox.2019.101364 ↗
29. 10.1016/j.ijpharm.2017.08.08410.1016/j.ijpharm.2017.08.084 ↗
30. 10.1016/j.heares.2013.05.01010.1016/j.heares.2013.05.010 ↗
31. 10.1007/s12035-014-8841-310.1007/s12035-014-8841-3 ↗
32. 10.3390/ijms24221654510.3390/ijms242216545 ↗
33. 10.1038/s41419-021-03463-810.1038/s41419-021-03463-8 ↗
34. 10.1371/journal.pone.029178010.1371/journal.pone.0291780 ↗
35. 10.1155/2021/559097310.1155/2021/5590973 ↗
36. 10.1016/j.fct.2019.11107910.1016/j.fct.2019.111079 ↗
37. 10.1016/j.heares.2023.10878310.1016/j.heares.2023.108783 ↗
38. 10.3389/fcell.2023.111977310.3389/fcell.2023.1119773 ↗
39. 10.1021/acs.jafc.4c0914310.1021/acs.jafc.4c09143 ↗
40. 10.1039/D2FO03301A10.1039/D2FO03301A ↗
41. 10.1177/205873842095955410.1177/2058738420959554 ↗
42. 10.1016/j.heares.2022.10851310.1016/j.heares.2022.108513 ↗